Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29765467 | 1.00 | AAK1 (0.46) | AAK1ALDH1A1MEN1MAPTTHRB | |
| SCHEMBL5868949 | 0.89 | AAK1 (0.50) | AAK1ALDH1A1MAPTHDAC3HDAC4 | |
| SCHEMBL5565178 | 0.88 | HDAC2 (0.47) | AAK1ALDH1A1MEN1MAPTTHRB | |
| SCHEMBL28399484 | 0.87 | NPC1 (0.47) | ALDH1A1MEN1MAPTTHRBKMT2A | |
| SCHEMBL5868813 | 0.86 | HDAC2 (0.53) | AAK1ALDH1A1MAPTHDAC2GAA | |
| SCHEMBL27889545 | 0.85 | RAB9A (0.51) | ALDH1A1MEN1MAPTKMT2AF10 | |
| SCHEMBL28626965 | 0.85 | AAK1 (0.46) | AAK1ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL5563026 | 0.85 | KCNQ3 (0.45) | AAK1ALDH1A1THRBHDAC1GAA | |
| SCHEMBL29770058 | 0.84 | NPC1 (0.56) | ALDH1A1MEN1MAPTKMT2AGAA | |
| SCHEMBL24253966 | 0.84 | POLB (0.56) | ALDH1A1MEN1MAPTTHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022174803-A1 | S-CONFIGURATION-CONTAINING AMINO BENZAMIDE PYRIDAZINONE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2022-08-25 | — | — | WO | disclosed |
| CN-113461602-B | Aniline compounds with HDAC (Histone deacetylase) inhibitory activity, preparation method, composition and application | 北京华氏信华科生物科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-113461602-A | Aniline compounds with HDAC (HDAC) inhibitory activity, preparation method, composition and application | 北京华氏信华科生物科技有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-111116469-A | HDAC inhibitor, preparation method, pharmaceutical composition and application thereof | 北京鑫开元医药科技有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| WO-2009037001-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-03-26 | — | — | WO | disclosed |
| EP-2038259-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | disclosed |
| WO-2008000643-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | AAK1 739/4885ALDH1A1 2532/4885MEN1 3642/4885 |
| US-20080021027-A1 | Novel benzimidazole derivatives | NR1H4, GPR119, GLP1R | AAK1 2309/4885ALDH1A1 1611/4885MEN1 3627/4885 |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | AAK1 2928/4885ALDH1A1 314/4885MEN1 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.